Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JOURNEY phase 3 trial of tezepelumab in adults with eosinophilic COPD
MOH_2025-04-03_014018Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2025-04-03_014018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-03_014018.